Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …

Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory
multiple myeloma (MM) have been poor because of a dearth of effective treatment options …

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial
workup, treatment, follow-up, and supportive care for patients with various plasma cell …

Despite many recent advances in therapy, there is still no plateau in overall survival curves
in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach …

Ciltacabtagene autoleucel (also known as cilta-cel) is a chimeric antigen receptor (CAR) T-
cell therapy that targets B-cell maturation antigen (BCMA) on the surface of cancer cells in B …

Peptide-based drug delivery systems have many advantages when compared to synthetic
systems in that they have better biocompatibility, biochemical and biophysical properties …

Background Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus
dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON …

We review drug conjugates combining a tumor-selective moiety with a cytotoxic agent as
cancer treatments. Currently, antibody-drug conjugates (ADCs) are the most common drug …

Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy
targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for …

Simple Summary During the last two decades, collaborative translational studies utilizing
novel methodologies have dramatically advanced our understanding of multiple myeloma …